Showing 1861-1870 of 5771 results for "".
- ScienceBased Health Announces New Ophthalmology Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-announces-new-ophthalmology-clinical-advisory-panel/2479314/ScienceBased Health (SBH) announced the formation of its new Ophthalmology Clinical Advisory Panel that will provide insight and recommendations on eye care industry trends and new developments. In addition, it will help guide and support the company’s educational initiatives in the ophthalmology
- Gyroscope Announces Research Collaboration with CMRI to Develop Gene Therapy Capsidshttps://modernod.com/news/gyroscope-announces-research-collaboration-with-cmri-to-develop-gene-therapy-capsids/2479315/Gyroscope Therapeutics announced the company has entered a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies. A team of researchers from CMRI
- CooperVision Announces Uniform Markings Across Blanchard Onefit Family of Scleral Lenseshttps://modernod.com/news/coopervision-announces-uniform-markings-across-blanchard-onefit-family-of-scleral-lenses/2479312/CooperVision Specialty EyeCare announced that lens markings are now uniform across the entire Blanchard Onefit family of scleral lenses, including Onefit MED and Onefit MED+. The uniform markings for front torics and toric haptics across the Onefit family aid in distinguishing whether quadrant sp
- Oyster Point Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial for Patients with Neurotrophic Keratopathyhttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-the-olympia-phase-2-clinical-trial-for-patients-with-neurotrophic-keratopathy/2479308/Oyster Point Pharma announced enrollment of the first subject in the OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK). “This is an exciting milestone as we continue to develop this potentially new tr
- Tarsus Announces Positive Results of Saturn-1 Trial Evaluating TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-announces-positive-results-of-saturn-1-trial-evaluating-tp-03-for-the-treatment-of-demodex-blepharitis/2479309/Tarsus Pharmaceuticals announced that all pre-specified primary and secondary endpoints were met for its pivotal Phase 2b/3 Saturn-1 trial evaluating the company’s novel investigational therapeutic, TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis. Results demons
- Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-safety-results-from-cohort-1-of-oasis-phase-1-2a-trial-of-cls-ax-for-the-treatment-of-wet-amd/2479292/Clearside Biomedical announced positive safety results from Cohort 1 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in six patients (n=6) with neovascular age-rel
- Visus Therapeutics Announces Executive Leadership Appointments in Operations, Research, Clinical Operations and Intellectual Propertyhttps://modernod.com/news/visus-therapeutics-announces-executive-leadership-appointments-in-operations-research-clinical-operations-and-intellectual-property/2479290/Visus Therapeutics announced the appointment of six new senior leaders, including Tim Grinstead as Chief Operating Officer; James Burke as Vice President of Research; Patrick Hughes, PhD, as Vice President of Pharmaceutical Development; Lisa Simpson as Vice President of Clinical Operations and Co
- EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Studyhttps://modernod.com/news/eyegate-pharma-announces-first-patient-dosed-for-pp-001-in-a-phase-2-proof-of-concept-ocular-surface-inflammation-study/2479289/EyeGate Pharmaceuticals announced the first patient dosed in phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an in
- Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics to Target Ophthalmic Diseaseshttps://modernod.com/news/oyster-point-pharma-announces-collaboration-with-adaptive-phage-therapeutics-to-target-ophthalmic-diseases/2479281/Oyster Point Pharma announced a newly formed research collaboration with Adaptive Phage Therapeutics (APT) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. APT’s PhageBank technology is engi
- Lighthouse Guild Announces the Naming of The Dorothy Strelsin Behavioral Health Clinichttps://modernod.com/news/lighthouse-guild-announces-the-naming-of-the-dorothy-strelsin-behavioral-health-clinic/2479278/In recognition of a long-time supporter of Lighthouse Guild, the organization has announced the naming of The Dorothy Strelsin Behavioral Health Clinic. Lighthouse Guild is very grateful for the steadfast support of Dorothy Strelsin, who in her lifetime made numerous initiatives possible, includi